These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11168182)

  • 1. MIC determination of fusidic acid and of ciprofloxacin using multidisk diffusion tests.
    Kronvall G
    Clin Microbiol Infect; 2000 Sep; 6(9):483-9. PubMed ID: 11168182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusidic acid disk diffusion testing of clostridium difficile can be calibrated using single-strain regression analysis.
    Oppenheimer M; Kronvall G; Karlsson I; Holst E
    Scand J Infect Dis; 2000; 32(6):633-6. PubMed ID: 11200373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calibration of fusidic acid disk diffusion susceptibility testing of Staphylococcus areus.
    Olsson-Liljequist B; Kõljalg S; Karlsson I; Kronvall G
    APMIS; 2002 Oct; 110(10):690-6. PubMed ID: 12583435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102).
    Biedenbach DJ; Rhomberg PR; Mendes RE; Jones RN
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):301-7. PubMed ID: 20159376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disk diffusion interpretive criteria for fusidic acid susceptibility testing of staphylococci by the National Committee for Clinical Laboratory Standards method.
    Coutant C; Olden D; Bell J; Turnidge JD
    Diagn Microbiol Infect Dis; 1996 May; 25(1):9-13. PubMed ID: 8831039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of MIC methods and tentative interpretive criteria for disk diffusion susceptibility testing using NCCLS methodology for fusidic acid.
    Skov R; Frimodt-Møller N; Espersen F
    Diagn Microbiol Infect Dis; 2001 Jul; 40(3):111-6. PubMed ID: 11502378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for gram-positive cocci.
    Toma E; Barriault D
    J Clin Microbiol; 1995 Jul; 33(7):1712-5. PubMed ID: 7665633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative post-antibiotic effect of five antibiotics against ten aerobic gram-positive cocci.
    Drabu YJ; Blakemore PH
    Drugs Exp Clin Res; 1990; 16(11):557-63. PubMed ID: 2151661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial antagonism between fusidic acid and ciprofloxacin.
    Uri JV
    Acta Microbiol Hung; 1993; 40(2):141-9. PubMed ID: 8184668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calibration of the disk diffusion test for trovafloxacin susceptibility testing of four anaerobic species.
    Kronvall G; Holst E
    Clin Microbiol Infect; 2000 Apr; 6(4):195-201. PubMed ID: 11168107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of fusidic acid (CEM-102) susceptibility testing reagents: broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus.
    Jones RN; Castanheira M; Rhomberg PR; Woosley LN; Pfaller MA
    J Clin Microbiol; 2010 Mar; 48(3):972-6. PubMed ID: 20053856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of ciprofloxacin combined with either fusidic acid or rifampicin against Staphylococcus aureus.
    Røder BL; Gutschik E
    J Antimicrob Chemother; 1989 Mar; 23(3):347-52. PubMed ID: 2732119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissemination of fusidic acid resistance among Staphylococcus aureus clinical isolates.
    Yu F; Liu Y; Lu C; Lv J; Qi X; Ding Y; Li D; Huang X; Hu L; Wang L
    BMC Microbiol; 2015 Oct; 15():210. PubMed ID: 26463589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel fusidic acid resistance determinant, fusF, in Staphylococcus cohnii.
    Chen HJ; Hung WC; Lin YT; Tsai JC; Chiu HC; Hsueh PR; Teng LJ
    J Antimicrob Chemother; 2015 Feb; 70(2):416-9. PubMed ID: 25313205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of difloxacin against canine bacterial isolates.
    van den Hoven R; Wagenaar JA; Walker RD
    J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
    Kayser FH; Wüst J
    Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):163-6. PubMed ID: 2060516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of nalidixic acid screening in fluoroquinolone-resistant typhoid salmonellae.
    Butt T; Khan MY; Ahmad RN; Salman M; Afzal RK
    J Coll Physicians Surg Pak; 2006 Jan; 16(1):31-4. PubMed ID: 16441985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin.
    Woodford N; Afzal-Shah M; Warner M; Livermore DM
    J Antimicrob Chemother; 2008 Oct; 62(4):766-8. PubMed ID: 18567573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fusidic acid resistance in Staphylococcus aureus nasal carriage strains in nine European countries.
    den Heijer CD; van Bijnen EM; Paget WJ; Stobberingh EE
    Future Microbiol; 2014; 9(6):737-45. PubMed ID: 25046521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.